Clinical outcome estimates based on treatment target limits of laboratory tests: Proposal for a plot visualizing effects and differences of medical target setting exemplified by glycemic control in diabetes

Clinical Chemistry and Laboratory Medicine

Volumn 44, Issue 3, 2006, Pages 327-332

  Jørgensen, Lone G M ^a,d   Petersen, Per Hyltoft ^b   Brandslund, Ivan ^a,c  

^a LILLEBAELT HOSPITAL   (Denmark)

^b UNIVERSITY OF BERGEN   (Norway)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d NONE   (Denmark)

Author keywords

Difference plot; Glycated hemoglobin; Treatment target

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C;

ARTICLE; DENMARK; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; HUMAN; LABORATORY TEST; MEASUREMENT; MODEL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; VALIDATION PROCESS;

BLOOD GLUCOSE; DENMARK; DIABETES MELLITUS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; LABORATORY TECHNIQUES AND PROCEDURES; REPRODUCIBILITY OF RESULTS; TECHNOLOGY ASSESSMENT, BIOMEDICAL; TREATMENT OUTCOME;

EID: 33644824836     PISSN: 14346621     EISSN: 14346621     Source Type: Journal    
DOI: 10.1515/CCLM.2006.057     Document Type: Article

References (20)

1. The American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2005;28:S4-36.
2. Panteghini M, Cuccia C, Bonetti G, Pagani F, Guibbini R, Bonini E. Rapid determination of brain natriuretic peptide in patients with acute myocardial infarction. Clin Chem Lab Med 2003;41:164-8.
3. Brandslund I, Jørgensen LG, Buhl A, Jakobsen E, Stahl M, Jacobsen A. Comparison of the microtiter plate version and a fully automated method to measure the extracellular domain of HER-2/neu in serum. Submitted.
4. Kasapis C, Thompson PD. The effects of physical activity on serum C-reactive protein and inflammatory markers: a systematic review. J Am Coll Cardiol 2005;45:1563-9.
5. Jørgensen LG, Brandslund I, Hyltoft Petersen P. Should we maintain the 95% reference intervals in the era of wellness testing? A concept paper. Clin Chem Lab Med 2004;42:747-51.
6. Jørgensen LG, Stahl M, Brandslund I, Hyltoft Petersen P, Borch-Johnsen K, de Fine Olivarius N. The plasma glucose reference interval in a low-risk population. The impact of the new WHO and ADA recommendations on diagnosis of diabetes mellitus II. Scand J Clin Lab Invest 2001;61:181-90.
7. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Geneva: WHO, 1999 (WHO/NCD/NCS/99.2).
8. European Diabetes Policy Group 1999. A desktop guide to type 2 diabetes. Diabet Med 1999;16:716-30 (http:// www.staff.ncl.ac.uk/philip.home/t2dg1999. htm#H).
9. Diabetes Control and Complication Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
10. Steffes M, Cleary P, Goldstein D, Little R, Wiedmeyer HM, Rohlfing C, et al. Haemoglobin A1c measurements over nearly two decades: sustaining comparable values throughout the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications Study. Clin Chem 2005;51:753-8.
11. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurements. Lancet 1986:307-10.
12. Ricos C, Cava F, Garcia-Lario JV, Hernandez A, Iglesias N, Jimenez CV, et al. The reference change value: a proposal to interpret laboratory reports in serial testing based on biological variation. Scand J Clin Lab Invest 2004;64:175-84.
13. Lytken Larsen M, Fraser CG, Hyltoft Petersen P. A comparison of analytical goals for haemoglobin A1c derived using different strategies. Ann Clin Biochem 1991;28:272-8.
14. The Danish Diabetes Association. Diabetesbehandling i Danmark - mål og midler 2005 (http://www.diabetes.dk).
15. Jørgensen LG, Brandslund I, Stahl M, Hyltoft Petersen P, Iversen S, Klitgaard N, et al. Upper reference limit, analytical quality specifications and clinical use of haemoglobin A1C. Scand J Clin Lab Invest 2002;62:609-22.
16. Sackett DL, Haynes RB. Evidence base of clinical diagnosis. The architecture of diagnostic research. Br Med J 2002;321:539-41.
17. Bruns DE. Laboratory-related outcome in healthcare. Clin Chem 2001;47:1547-52.
18. Berger VW. Ensuring the comparability of comparison groups: is randomisation enough? Control Clin Trials 2004;25:515-24.
19. Siest G. Study of reference values and biological variation: a necessity and a model for Preventive Medicine Centres. Clin Chem Lab Med 2004;42:810-6.
20. Hyltoft Petersen P, Stöckl D, Blaabjerg O, Pedersen B, Birkemose E, Thienpont L, et al. Graphical interpretation of analytical data from comparison of a field method with a reference method by use of difference plots. Clin Chem 1997;43:2039-46.